Puma Biotechnology (NASDAQ:PBYI - Get Free Report) was downgraded by investment analysts at Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating in a research note issued on Saturday,Weiss Ratings reports.
Separately, Wall Street Zen raised shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Friday, September 5th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Puma Biotechnology has an average rating of "Moderate Buy" and a consensus target price of $7.00.
Read Our Latest Report on Puma Biotechnology
Puma Biotechnology Stock Up 3.8%
Shares of Puma Biotechnology stock opened at $5.23 on Friday. The firm's 50 day moving average price is $5.00 and its 200-day moving average price is $3.94. The company has a quick ratio of 1.62, a current ratio of 1.73 and a debt-to-equity ratio of 0.10. Puma Biotechnology has a 52-week low of $2.32 and a 52-week high of $6.07. The company has a market cap of $263.44 million, a P/E ratio of 5.34 and a beta of 1.39.
Institutional Trading of Puma Biotechnology
Several institutional investors and hedge funds have recently bought and sold shares of PBYI. CWM LLC lifted its stake in Puma Biotechnology by 214.1% during the 2nd quarter. CWM LLC now owns 9,462 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 6,450 shares during the period. Cerity Partners LLC acquired a new position in shares of Puma Biotechnology in the 2nd quarter valued at $36,000. Causeway Capital Management LLC acquired a new position in shares of Puma Biotechnology in the 1st quarter valued at $42,000. Savant Capital LLC acquired a new position in shares of Puma Biotechnology in the 2nd quarter valued at $44,000. Finally, Ethic Inc. acquired a new position in shares of Puma Biotechnology in the 2nd quarter valued at $51,000. 61.29% of the stock is currently owned by institutional investors and hedge funds.
About Puma Biotechnology
(
Get Free Report)
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Puma Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Puma Biotechnology wasn't on the list.
While Puma Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
